For the first time, a pharmacotherapy for overweight and obesity has reduced cardiovascular events in patients with established cardiovascular disease in the absence of type 2 diabetes.
New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight
Randomized trial evidence that weight loss can yield cardiovascular benefits independent of antidiabetic effects has been elusive. Two major ongoing trials are likely to change that, with potentially big implications for clinical practice.